Shares dropped 11.4% following Q1 results as investors reacted negatively to cautious outlook and underwhelming financial updates despite clinical progress, signaling disappointment with the company's near-term prospects and margin pressures.

• Collaboration with Astellas on VIR-5500 in prostate cancer advanced, with deal closure and joint clinical plans underway.
• Phase I data showed a favorable safety profile for VIR-5500, notably no Grade 3 cytokine release syndrome and potential outpatient administration benefits.
• Early signs of durable responses observed in heavily pretreated metastatic castration-resistant prostate cancer (MCRPC) patients, including some with liver metastases.
• Dose escalation ongoing with expansion cohorts addressing both RLT-naive and post-RLT patient populations, plus early-line combination trials starting soon.
• Financial commentary indicated concerns around guidance and margin trends, which were the likely drivers of the negative investor reaction despite clinical updates.